Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 179

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 179
---
, net

    389

    381

    Comprehensive loss
     
    $
    (86,092
    )
     
    $
    (68,753
    )

    Net loss per share, basic and diluted
     
    $
    (1.51
    )
     
    $
    (1.62
    )

    Weighted-average shares used to compute net loss    per share, basic and diluted

    57,217,746

    42,704,876

See accompanying notes to financial statements.

117

Tyra Biosciences, Inc.

Statements of Stockholders’ Equity(in thousands, except share amounts)

    Common Stock

    AdditionalPaid-In Capital

    Accumulated Other Comprehensive Income

    AccumulatedDeficit

    TotalStockholders’Equity

    Shares

    Amount

    Balance at December 31, 2022

    42,353,550

    $
    4

    $
    353,521

    $
    —

    $
    (95,696
    )
     
    $
    257,829

    Issuance of common stock     under benefit plans

    464,596

    —

    1,537

    —

    —

    1,537

    Vesting of shares of common   stock subject to repurchase

    206,488

    —

    124

    —

    —

    124

    Stock-based compensation

    —

    —

    13,525

    —

    —

    13,525

    Unrealized gain on marketable    securities available-for-sale, net

    —

    —

    —

    381

    —

    381

    Net loss

    —

    —

    —

    —

    (69,134
    )

    (69,134
    )

    Balance at December 31, 2023

    43,024,634

    $
    4

    $
    368,707

    $
    381

    $
    (164,830
    )
     
    $
    204,262

    Issuance of common stock under    Private Placement, net of issuance    costs of $0.2 million

    9,286,023

    1

    120,557

    —

    —

    120,558

    Iss